scispace - formally typeset
H

Hannah D. G. Fiji

Researcher at University of California, Los Angeles

Publications -  7
Citations -  485

Hannah D. G. Fiji is an academic researcher from University of California, Los Angeles. The author has contributed to research in topics: Geranylgeranylation & RHOA. The author has an hindex of 6, co-authored 7 publications receiving 444 citations.

Papers
More filters
Journal ArticleDOI

Small-molecule inhibitors of protein geranylgeranyltransferase type I.

TL;DR: Small molecules that inhibit the geranylgeranylation of K-Ras4B and RhoA by protein Geranylgeranyltransferase type I (GGTase-I) were identified from chemical genetic screens of heterocycles synthesized through phosphine catalysis of allenes.
Journal ArticleDOI

Inhibitors of Protein Geranylgeranyltransferase I and Rab Geranylgeranyltransferase Identified from a Library of Allenoate-derived Compounds

TL;DR: The identification and characterization of small molecule inhibitors of GGTase-I (GGTI) with two novel scaffolds from a library consisting of allenoate-derived compounds and the discovery of a common structural feature for RabGGTase inhibitors: the presence of a characteristic six-atom aliphatic tail attached to the penta-substituted pyrrolidine core.
Journal ArticleDOI

In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I

TL;DR: In vivo effects of the novel GGTI compound P61A6 are investigated by using a human pancreatic cancer xenograft model in mice and show an excellent antitumor effect, providing evidence that protein GGTase-I may be a valid target for cancer therapy.
Journal ArticleDOI

Aplexone targets the HMG-CoA reductase pathway and differentially regulates arteriovenous angiogenesis

TL;DR: It is shown that the caudal vein plexus in zebrafish forms by endothelial cell sprouting, migration and anastomosis, providing a venous-specific angiogenesis model, and multiple lines of evidence indicate that aplexone differentially regulates arteriovenousAngiogenesis by targeting the HMG-CoA reductase (HMGCR) pathway.